[go: up one dir, main page]

WO2012112340A3 - Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals - Google Patents

Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals Download PDF

Info

Publication number
WO2012112340A3
WO2012112340A3 PCT/US2012/024137 US2012024137W WO2012112340A3 WO 2012112340 A3 WO2012112340 A3 WO 2012112340A3 US 2012024137 W US2012024137 W US 2012024137W WO 2012112340 A3 WO2012112340 A3 WO 2012112340A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
nervous system
treating
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/024137
Other languages
French (fr)
Other versions
WO2012112340A2 (en
Inventor
Yuanlong Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2013009544A priority Critical patent/MX2013009544A/en
Priority to US13/985,884 priority patent/US20130324608A1/en
Priority to JP2013554477A priority patent/JP2014514248A/en
Priority to RU2013142437/15A priority patent/RU2013142437A/en
Priority to BR112013020802A priority patent/BR112013020802A2/en
Priority to CA2827715A priority patent/CA2827715A1/en
Priority to CN201280018853.7A priority patent/CN103764136A/en
Priority to EP12747397.3A priority patent/EP2675447A4/en
Application filed by Nestec SA filed Critical Nestec SA
Priority to AU2012218094A priority patent/AU2012218094A1/en
Publication of WO2012112340A2 publication Critical patent/WO2012112340A2/en
Anticipated expiration legal-status Critical
Priority to ZA2013/06990A priority patent/ZA201306990B/en
Publication of WO2012112340A3 publication Critical patent/WO2012112340A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/20—Inorganic substances, e.g. oligoelements
    • A23K20/30—Oligoelements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods and compositions for treating, reducing, or preventing damage to at least one component of the nervous system of an animal are disclosed. The methods comprise administering to the animal a composition comprising UFA and NORC in an amount effective to treat, reduce, or prevent damage to at least one component of the nervous system. Methods extending the prime years of an animal's life, improving the quality of life, and promoting health and wellness of an animal using compositions comprising UFA and NORC, and optionally, antioxidant(s) and/or B vitamins are also disclosed.
PCT/US2012/024137 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals Ceased WO2012112340A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201280018853.7A CN103764136A (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
JP2013554477A JP2014514248A (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing or preventing damage to the nervous system of animals
RU2013142437/15A RU2013142437A (en) 2011-02-18 2012-02-07 METHODS AND COMPOSITIONS FOR TREATMENT, REDUCTION OR PREVENTION OF DAMAGE TO THE NERVOUS ANIMAL SYSTEM
BR112013020802A BR112013020802A2 (en) 2011-02-18 2012-02-07 methods and compositions for treating, reducing or preventing damage to the nervous system of animals
CA2827715A CA2827715A1 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
MX2013009544A MX2013009544A (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals.
US13/985,884 US20130324608A1 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing or preventing damage to the nervous system of animals
EP12747397.3A EP2675447A4 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
AU2012218094A AU2012218094A1 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
ZA2013/06990A ZA201306990B (en) 2011-02-18 2013-09-17 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161463594P 2011-02-18 2011-02-18
US61/463,594 2011-02-18

Publications (2)

Publication Number Publication Date
WO2012112340A2 WO2012112340A2 (en) 2012-08-23
WO2012112340A3 true WO2012112340A3 (en) 2014-04-17

Family

ID=46673093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/024137 Ceased WO2012112340A2 (en) 2011-02-18 2012-02-07 Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals

Country Status (11)

Country Link
US (1) US20130324608A1 (en)
EP (1) EP2675447A4 (en)
JP (1) JP2014514248A (en)
CN (1) CN103764136A (en)
AU (1) AU2012218094A1 (en)
BR (1) BR112013020802A2 (en)
CA (1) CA2827715A1 (en)
MX (1) MX2013009544A (en)
RU (1) RU2013142437A (en)
WO (1) WO2012112340A2 (en)
ZA (1) ZA201306990B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014108808A2 (en) * 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
RU2667640C1 (en) 2013-12-19 2018-09-21 Тассос ГЕОРГИУ Compositions of omega 3 fatty acids to treat diseases which involve damage to nervous system
CN104146253A (en) * 2014-08-13 2014-11-19 胡安然 Full-nutrition formulated food for epilepsy
WO2018209022A2 (en) 2017-05-10 2018-11-15 University Of Rochester Methods of treating neuropsychiatric disorders
CN109300527A (en) * 2018-12-14 2019-02-01 苏州大学 Recommended method of dietary information
US20230016955A1 (en) * 2020-06-01 2023-01-19 Corona Feed Additives, L.L.C. Animal Contraceptive
JP2023528090A (en) * 2020-06-01 2023-07-03 コロナ フィード アディティブス エル．エル．シー． Porcine contraceptive compositions, systems and methods
CN114144239B (en) * 2020-06-16 2024-03-19 Md保健株式会社 Composition for preventing or treating neurological or mental disorders containing extracellular vesicles derived from Lactobacillus paracasei
CN113368171A (en) * 2021-06-18 2021-09-10 长江大学 Application of medlar in preparation of medicine for preventing cognitive dysfunction caused by radiotherapy
CN113322213B (en) * 2021-07-09 2022-05-13 吉林大学 A kind of Lactobacillus paracasei Jlus66 bacterial agent and application with the function of improving memory impairment

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965552A (en) * 1991-01-07 1999-10-12 Pherin Pharmaceuticals, Inc. Androstane steroids as neurochemical initators of change in human hypothalamic compositions and methods
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6469049B1 (en) * 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20040186488A1 (en) * 2003-03-17 2004-09-23 Droese Karl William Method of peripheral nerve reconstruction using a micro suction connector
US6858646B2 (en) * 1999-05-05 2005-02-22 Universite Du Quebec A Montreal Neuroprotective composition and uses thereof
US20050131212A1 (en) * 2001-08-24 2005-06-16 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of brain damage
US20080103092A1 (en) * 2005-03-11 2008-05-01 Pomytkin Igor A Methods for Intradermal, Transdermal or Transmucosal Delivery of Biologically Active Substances
US20090181879A1 (en) * 2005-07-08 2009-07-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Methods for Monitoring Neuroinflammatory Destruction of Neurons and for Treating Diseases Having an Inflammatory component related to phospholipase A2
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders
US20090305323A1 (en) * 2005-10-24 2009-12-10 Kaddurah-Daouk Rima F Lipidomics approaches for central nervous system disorders
US20100233304A1 (en) * 2008-01-04 2010-09-16 Yuanlong Pan Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US20100254951A1 (en) * 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308832A (en) * 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
WO1998008500A1 (en) * 1996-08-26 1998-03-05 Board Of Regents, The University Of Texas System Hypertonic arginine compositions and methods
ES2313895T3 (en) * 1999-06-14 2009-03-16 Henry Ford Health System DONATORS OF NITRIC OXIDE TO INDUCE NEUROGENESIS.
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6967219B2 (en) * 2001-10-12 2005-11-22 Cornell Research Foundation, Inc. Reversing or preventing premature vascular senescence
JP2003261456A (en) * 2002-03-08 2003-09-16 Howaizu:Kk Prevention of brain aging
US6951658B1 (en) * 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
CA2598525A1 (en) * 2005-02-22 2006-08-31 Mochida Pharmaceutical Co., Ltd. Nerve regeneration promoting agent
ES2365628T3 (en) * 2005-08-26 2011-10-07 Nestec S.A. COMPOSITIONS AND METHODS TO IMPROVE FUNCTIONAL VASCULAR INTEGRITY, CELL SURVIVAL AND REDUCTION OF APOPTOSIS AFTER AN ISCHEMICAL EPISODE IN THE BRAIN.
MX2008002623A (en) * 2005-08-26 2008-03-18 Nestec Sa Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain.

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965552A (en) * 1991-01-07 1999-10-12 Pherin Pharmaceuticals, Inc. Androstane steroids as neurochemical initators of change in human hypothalamic compositions and methods
US6858646B2 (en) * 1999-05-05 2005-02-22 Universite Du Quebec A Montreal Neuroprotective composition and uses thereof
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6469049B1 (en) * 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
US20050131212A1 (en) * 2001-08-24 2005-06-16 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of brain damage
US20040186488A1 (en) * 2003-03-17 2004-09-23 Droese Karl William Method of peripheral nerve reconstruction using a micro suction connector
US20100254951A1 (en) * 2005-02-22 2010-10-07 Mochida Pharmaceutical Co., Ltd. Nerve Regeneration Promoting Agent
US20080103092A1 (en) * 2005-03-11 2008-05-01 Pomytkin Igor A Methods for Intradermal, Transdermal or Transmucosal Delivery of Biologically Active Substances
US20090181879A1 (en) * 2005-07-08 2009-07-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Methods for Monitoring Neuroinflammatory Destruction of Neurons and for Treating Diseases Having an Inflammatory component related to phospholipase A2
US20090305323A1 (en) * 2005-10-24 2009-12-10 Kaddurah-Daouk Rima F Lipidomics approaches for central nervous system disorders
US20100233304A1 (en) * 2008-01-04 2010-09-16 Yuanlong Pan Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
US20090214484A1 (en) * 2008-02-22 2009-08-27 Nikolay Mironov Stem cell therapy for the treatment of central nervous system disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2675447A4 *

Also Published As

Publication number Publication date
ZA201306990B (en) 2015-04-29
EP2675447A2 (en) 2013-12-25
MX2013009544A (en) 2013-09-26
AU2012218094A1 (en) 2013-08-29
JP2014514248A (en) 2014-06-19
WO2012112340A2 (en) 2012-08-23
CN103764136A (en) 2014-04-30
EP2675447A4 (en) 2015-04-22
RU2013142437A (en) 2015-03-27
BR112013020802A2 (en) 2016-10-04
US20130324608A1 (en) 2013-12-05
CA2827715A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
WO2012112340A3 (en) Methods and compositions for treating, reducing, or preventing damage to the nervous system of animals
MX348898B (en) Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals.
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
WO2009089494A3 (en) Pharmaceutical compositions
WO2015157559A3 (en) 10',11'-modified saxitoxins useful for the treatment of pain
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2009039460A3 (en) Co-administration of pimavanserin with other agents
PH12015500756A1 (en) Methods for enhancing the effect of egcg on mitigating skeletal muscle loss
WO2012087742A3 (en) Methods and compositions suitable for managing blood glucose in animals
WO2015051543A8 (en) Cancer treatment with combination of plinabulin and taxane
WO2011090270A3 (en) Composition containing osmotin for preventing and treating neurological disorders
WO2010081091A3 (en) Therapeutic compositions for treatment of corneal disorders
PH12012500773A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
NZ701133A (en) Composition for treating metabolic disorders
WO2011156811A3 (en) Compounds for treatment of bovine mastitis
WO2011044523A3 (en) Compositions and methods for treating obesity
WO2011153377A3 (en) Methods and compositions for treating a subject for central nervous system (cns) injury
MX2011012310A (en) Treatment of heart failure with normal ejection fraction.
MX347263B (en) Methods for increasing the production or activity of catalase.
WO2012106058A3 (en) Animal treatments
WO2009126695A3 (en) Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes
WO2012103282A3 (en) Methods and compositions for treating alzheimer's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12747397

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013554477

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2827715

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13985884

Country of ref document: US

Ref document number: MX/A/2013/009544

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1301004542

Country of ref document: TH

ENP Entry into the national phase

Ref document number: 2012218094

Country of ref document: AU

Date of ref document: 20120207

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012747397

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013142437

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013020802

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013020802

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130815